BioInteractions Launches Revolutionary Surface-Active Systems for Medical Devices
BioInteractions has introduced Surface-Active Systems (SAS), a novel category of medical device coatings designed to enhance performance and patient safety. This innovative technology, launched by the company, offers long-lasting, site-specific protection against infections and blood clots, potentially reducing the need for systemic drugs.
SAS comprises two product families: Surface-Active Therapeutics and Surface-Active Materials. The former includes AstutePlus Antithrombogenic and TridAntz Antimicrobial, providing sustained therapeutic performance without systemic drug exposure. The latter, such as Assist Lubricious, boosts device performance in challenging environments.
SAS aims to tackle demands in infection prevention, thrombosis control, and device longevity across various medical devices. Arjun Luthra, Commercial Director at BioInteractions, describes SAS as a paradigm shift in medical device coating technologies. Nicholas Inston, President-Elect of the Vascular Access Society, highlights the benefits of SAS coatings for dialysis catheter use.
BioInteractions, with no available information on its founder(s), seeks to set a new benchmark in medical device coatings. SAS, with its zero-leaching properties and long-lasting protection, promises to improve implant performance, enhance patient safety, and evolve therapeutic outcomes. The company's ambition is to make a significant impact on the medical device industry with this innovative coating solution.
Read also:
- Zigbee and LoRa Low-Power Internet of Things (IoT) Network Protocols: The Revolution in Data Transmission and Networking
- Quarterly Financial Report Discussion for Burning Rock Biotech Limited in 2022's Second Quarter
- NarcX+ Meets DEA Standards, Destroys Fentanyl in Minutes
- The Fascination of Magnetic Forces: Exploring Attraction and Repulsion in Daily Routine and Industrial Uses
